"Bile Ducts, Intrahepatic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.
| Descriptor ID |
D001653
|
| MeSH Number(s) |
A03.159.183.158 A03.620.150
|
| Concept/Terms |
Bile Ducts, Intrahepatic- Bile Ducts, Intrahepatic
- Bile Duct, Intrahepatic
- Duct, Intrahepatic Bile
- Ducts, Intrahepatic Bile
- Intrahepatic Bile Duct
- Intrahepatic Bile Ducts
|
Below are MeSH descriptors whose meaning is more general than "Bile Ducts, Intrahepatic".
Below are MeSH descriptors whose meaning is more specific than "Bile Ducts, Intrahepatic".
This graph shows the total number of publications written about "Bile Ducts, Intrahepatic" by people in this website by year, and whether "Bile Ducts, Intrahepatic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 2 | 3 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 7 | 0 | 7 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 3 | 3 | 6 |
| 2012 | 4 | 0 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 3 | 2 | 5 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 10 | 10 |
| 2023 | 0 | 10 | 10 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bile Ducts, Intrahepatic" by people in Profiles.
-
Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol. 2024 03; 8:e2300544.
-
Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev. 2023 10 02; 32(10):1338-1347.
-
Great Debates: Neoadjuvant Therapy Should be Routinely Given for High-Risk Cholangiocarcinoma. Ann Surg Oncol. 2023 12; 30(13):7960-7965.
-
?-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus. World J Gastroenterol. 2023 Jul 28; 29(28):4416-4432.
-
Trends in mortality of liver cancer before and during the COVID-19 pandemic, 2017-2021. Liver Int. 2023 09; 43(9):1865-1870.
-
Predicting cholangiocarcinoma in primary sclerosing cholangitis: using artificial intelligence, clinical and laboratory data. BMC Gastroenterol. 2023 Apr 19; 23(1):129.
-
ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome. Hepatology. 2023 11 01; 78(5):1337-1351.
-
Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatol Commun. 2023 03 01; 7(3).
-
Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort. ESMO Open. 2023 02; 8(1):100783.
-
Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes? HPB (Oxford). 2023 04; 25(4):472-480.